Hck和Lyn激酶与慢性髓细胞性白血病的关系

Src家族激酶（Sre—family kinase,SFK）是一组非受体型酪氨酸蛋白激酶,其家族成员Hck （hemopoietic cell kinase）和Lyn（v-yes-1 Yanaguchi sarcoma viral related oncogene homolog）激酶在慢性髓细胞性白血病（chronic myelogenous leukemia,CML）细胞中被BCR—ABL异常激活,并作用于多种细胞内信号转导分子,影响细胞的增殖、凋亡和迁移。深入研究SFK在CML发生和发展中的作用,对进一步认识CML发病机制及其靶向性治疗有着重要的实际意义。     

伊马替尼血药浓度监测指导慢性粒细胞白血病患者的研究

目的 观察是否可以通过对伊马替尼(Imatinib,IM)进行血药浓度监测提高疗效,减少药物不良反应。方法 选取2013~2018年就诊于我院的慢性粒细胞白血病(chronic myelogenous leukemia, CML)患者,分为试验组(药物监测组),对照组(常规经验治疗组)。对服药3个月、6个月、12个月、18个月,进行疗效及不良反应评估及比较。结果 共有51人入选此次临床试验。其中试验组35人,对照组16人。结果 服用伊马替尼400mg/d时,血药浓度568.00~3 989.66ng/ml,均数(标准差):1 716.46ng/ml(788.96);服用伊马替尼300mg/d时,血药浓度720.89~1 497.11ng/ml,均数(标准差):971.67ng/ml(204.02)。达到主要分子学反应(major molecular response, MMR)的伊马替尼血药浓度高于未达到稳态时的伊马替尼血药浓度。两组不良反应评级有统计学差异。试验组III级及以上不良反应发生率明显小于对照组。结论 伊马替尼的稳态血浆药物谷浓度存在较大个体差异,这种个体差异与疗效和不良反应存在相关性。通过治疗药物监测(therapeutic drug monitoring, TDM)可以在确保疗效的同时,减少伊马替尼在治疗慢性粒细胞白血病中的不良反应。结果尚需大样本临床试验进一步验证。伊马替尼药物代谢个体差异的原因需要大样本遗传药理学研究进一步探讨。     

Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia

Although imatinib is an effective treatment for chronic myelogenous leukemia (CML), and nearly all patients treated with imatinib attain some form of remission, imatinib does not completely eliminate leukemia. Moreover, if the imatinib treatment is stopped, most patients eventually relapse (Cortes et al. in Clin. Cancer Res. 11:3425–3432, 2005). In Kim et al. (PLoS Comput. Biol. 4(6):e1000095, 2008), the authors presented a mathematical model for the dynamics of CML under imatinib treatment that incorporates the anti-leukemia immune response. We use the mathematical model in Kim et al. (PLoS Comput. Biol. 4(6):e1000095, 2008) to study and numerically simulate strategic treatment interruptions as a potential therapeutic strategy for CML patients. We present the results of numerous simulated treatment programs in which imatinib treatment is temporarily stopped to stimulate and leverage the anti-leukemia immune response to combat CML. The simulations presented in this paper imply that treatment programs that involve strategic treatment interruptions may prevent leukemia from relapsing and may prevent remission for significantly longer than continuous imatinib treatment. Moreover, in many cases, strategic treatment interruptions may completely eliminate leukemic cells from the body. Thus, strategic treatment interruptions may be a feasible clinical approach to enhancing the effects of imatinib treatment for CML. We study the effects of both the timing and the duration of the treatment interruption on the results of the treatment. We also present a sensitivity analysis of the results to the parameters in the mathematical model.     

Hematopoietic Stem Cells,Leukemic Stem Cells and Chronic Myelogenous Leukemia

Blood-related cancers, or leukemias, have been shown to arise from a rare subset of cells that escape normal regulation and drive the formation and growth of the tumor. The finding that these so-called cancer stem cells, or leukemic stem cells (LSC), can be purified away from the other cells in the tumor allows their precise analysis to identify candidate molecules and regulatory pathways that play a role in progression, maintenance, and spreading of leukemias. The analyses of the other, numerically dominant, cells in the tumor, while also interesting, do not directly interrogate these key properties of malignancies. Mouse models of human myeloproliferative disorder and acute myelogenous leukemia have highlighted the remarkable conservation of disease mechanisms between both species. They can now be used to identify the LSC for each type of human leukemia and understand how they escape normal regulation and become malignant. Given the clinical importance of LSC identification, the insights gained through these approaches will quickly translate into clinical applications and lead to improved treatments for human leukemias.     

Stability Analysis of a Simplified Yet Complete Model for Chronic Myelogenous Leukemia

We analyze the asymptotic behavior of a partial differential equation (PDE) model for hematopoiesis. This PDE model is derived from the original agent-based model formulated by Roeder (Nat. Med. 12(10):1181–1184, 2006), and it describes the progression of blood cell development from the stem cell to the terminally differentiated state.     

Modeling Imatinib-Treated Chronic Myelogenous Leukemia: Reducing the Complexity of Agent-Based Models

We develop a model for describing the dynamics of imatinib-treated chronic myelogenous leukemia. Our model is based on replacing the recent agent-based model of Roeder et al. (Nat. Med. 12(10):1181–1184, 2006) by a system of deterministic difference equations. These difference equations describe the time-evolution of clusters of individual agents that are grouped by discretizing the state space. Hence, unlike standard agent-base models, the complexity of our model is independent of the number of agents, which allows to conduct simulation studies with a realistic number of cells. This approach also allows to directly evaluate the expected steady states of the system. The results of our numerical simulations show that our model replicates the averaged behavior of the original Roeder model with a significantly reduced computational cost. Our general approach can be used to simplify other similar agent-based models. In particular, due to the reduced computational complexity of our technique, one can use it to conduct sensitivity studies of the parameters in large agent-based systems.     

The Mechanism of Action of Splenic Irradiation in Chronic Myelogenous Leukemia

The mechanism of action of splenic irradiation in the induction of a remission in chronic myelogenous leukemia was investigated in six patients using a leukocyte kinetic approach. The leukocytes were labelled in vitro with radioactive diisopropylfluorophosphate-32 and returned to the circulation. The effect of treatment on the rate of change of leukocyte specific activity was determined. The results suggest (1) that irradiation of the spleen damages granulopoietic cells as they cycle back and forth between the spleen, blood and other extravascular compartments; (2) that damage to exchangeable granulopoietic cells in transit through the irradiated spleen may explain the long remission often encountered after this form of therapy.     

Studies on the Longevity,Sequestration and Release of the Leukocytes in Chronic Myelogenous Leukemia

The intravascular life-span of leukocytes labelled in vitro with radioactive di-isopropylfluorophosphate was studied in 12 patients with chronic myelogenous leukemia (CML). In relapse, leukocyte specific activity (LSA) disappeared slowly; in remission, LSA curves approached normal and only a small proportion of LSA disappeared slowly. The level of maturation of the leukocytes that persisted in the blood was investigated by a leukocyte fractionation technique which excluded immature myeloid cells from leukocyte samples. The influence of extracorpuscular factors upon the pattern of disappearance of LSA was investigated by means of cross-transfusion experiments, and LSA curves obtained with in vitro and in vivo labelling were compared. The results suggest that: (1) the intravascular life-span of the mature leukemic neutrophil is prolonged in relapse and in remission; (2) intrinsically abnormal leukocytes are sequestered in an extravascular pool(s) but recycling occurs; (3) extracorpuscular factors modify the LSA curves; (4) exchange of leukocytes between intravascular and extravascular pools may not occur in relapse; and (5) the intravascular and extravascular pools constitute a self-sustaining pool(s) not replenished from a non-miscible precursor pool.     

慢性髓细胞性白血病病人骨髓单个核细胞中差异表达基因的筛选

目的:筛选慢性髓细胞性白血病(CML)病人骨髓单个核细胞与正常人的差异表达基因,探讨CML的发病机制.方法:提取正常人和CML病人单个核细胞的RNA,逆转录成cDNA并用地高辛标记,应用全基因组表达谱基因芯片对差异表达基因进行研究,采用Jubilant病理/疾病分类法对CML相关差异表达基因进行分析.结果:共筛选出CM...     

Isolation and Characterization of a Novel Equol-Producing Bacterium from Human Feces

An equol-producing bacterium was newly isolated from the feces of healthy humans and its morphological and biochemical properties were characterized. The cells were obligate anaerobes. They were non-sporulating, non-motile, gram-positive bacilliform bacteria with a pleomorphic morphology. The strain was catalase-positive, and oxidase-, urease-, and indole-negative. The only other sugar utilized by the strain was glycerin. The strain also degraded gelatin, but not esculin. It was most closely related to Eggerthella hongkongensis HKU10, with 93.3% 16S rDNA nucleotide sequence homology. Based on these features, the isolate was identified as a novel species of the genus Eggerthella. It was named Eggerthella sp. YY7918. Strain YY7918 converted substrates daidzein and dihydrodaidzein into S-equol, but did not convert daidzin, glysitein, genistein, or formononetin into it. An antimicrobial susceptibility assay indicated that strain YY7918 was susceptible to aminoglycoside-, tetracycline-, and new quinolone-antibiotics.     

Isolation and Characterization of a Novel Antialgal Allelochemical from Phragmites communis

Antialgal allelochemicals were isolated from Phragmites communis Tris. The isolated allelopathic fraction showed strong inhibition activity on the growth of Chlorella pyrenoidosa and Microcystis aeruginosa but had no inhibition on Chlorella vulgaris. The 50% effective concentrations (EC₅₀) of the allelopathic fractions on C. pyrenoidosa and M. aeruginosa were 0.49 and 0.79 mg/liter, respectively. The allelopathic activity of the fraction was species-specific. The isolated allelopathic fraction caused metal ion leakage from algal cells. The fraction decreased the activities of antioxidant enzymes, such as superoxide dismutase and peroxidase. The addition of the isolated fraction increased the concentration of unsaturated lipid fatty acids in cell membrane of C. pyrenoidosa and M. aeruginosa. This caused a change in plasma membrane integrity and the leakage of ions in the protoplast. The allelopathic compound was identified by nuclear magnetic resonance and gas chromatography-mass spectrometry as ethyl 2-methylacetoacetate. Synthesized ethyl 2-methylacetoacetate also showed allelopathic activity on C. pyrenoidosa and M. aeruginosa. The EC₅₀ of synthesized ethyl 2-methylacetoacetate on C. pyrenoidosa and M. aeruginosa were 0.49 and 0.65 mg/liter, respectively.     

Expression and Activity of Fyn Mediate Proliferation and Blastic Features of Chronic Myelogenous Leukemia

The BCR-ABL1 oncogene is a tyrosine kinase that activates many signaling pathways, resulting in the induction of chronic myeloid leukemia (CML). Kinase inhibitors, such as imatinib, have been developed for the treatment of CML; however, the terminal, blast crisis phase of the disease remains a clinical challenge. Blast crisis CML is difficult to treat due to resistance to tyrosine kinase inhibitors, increased genomic instability and acquired secondary mutations. Our recent studies uncovered a role for Fyn in promoting BCR-ABL1 mediated cell growth and sensitivity to imatinib. Here we demonstrate that Fyn contributes to BCR-ABL1 induced genomic instability, a feature of blast crisis CML. Bone marrow cells and mouse embryonic fibroblasts derived from Fyn knockout mice transduced with BCR-ABL1 display slowed growth and clonogenic potential as compared to Fyn wild-type BCR-ABL1 expressing counterparts. K562 cells overexpressing constitutively active Fyn kinase were larger in size and displayed an accumulation of genomic abnormalities such as chromosomal aberrations and polyploidy. Importantly, loss of Fyn protected mouse embryonic fibroblast cells from increased number of chromosomal aberrations and fragments induced by BCR-ABL1. Together, these results reveal a novel role for Fyn in regulating events required for genomic maintenance and suggest that Fyn kinase activity plays a role in the progression of CML to blast crisis.     

Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia

in silico modeling, using Psipred and ExPASy servers was employed to determine the structural elements of Bcr-Abl oncoprotein (p210^BCR-ABL) isoforms, b2a2 and b3a2, expressed in Chronic Myelogenous Leukemia (CML). Both these proteins are tyrosine kinases having masses of 210-kDa and differing only by 25 amino acids coded by the b3 exonand an amino acidsubstitution (Glu903Asp). The secondary structure elements of the two proteins show differences in five α-helices and nine β-strands which relates to differences in the SH₃, SH₂, SH1 and DNA-binding domains. These differences can result in different roles played by the two isoforms in mediating signal transduction during the course of CML.     

Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cells in Chronic Myelogenous Leukemia

We describe here a simple model for the interaction between leukemic cells and the autologous immune response in chronic phase chronic myelogenous leukemia (CML). This model is a simplified version of the model we proposed in Clapp et al. (Cancer Res 75:4053–4062, 2015). Our simplification is based on the observation that certain key characteristics of the dynamics of CML can be captured with a three-compartment model: two for the leukemic cells (stem cells and mature cells) and one for the immune response. We characterize the existence of steady states and their stability for generic forms of immunosuppressive effects of leukemic cells. We provide a complete co-dimension one bifurcation analysis. Our results show how clinical response to tyrosine kinase inhibitors treatment is compatible with the existence of a stable low disease, treatment-free steady state.     

非典型肺炎病例标本中新型冠状病毒的分离与鉴定

目的对非典型肺炎的病原体进行分离鉴定,为该病的诊断、预防和治疗提供依据。方法采用细胞培养和乳鼠接种法,从非典型肺炎病例标本中分离致病病原体,通过电镜形态学、血清学和动物致病性观察及RTPCR扩增与部分基因序列分析,对分离的病原体进行鉴定。结果成功地从死亡病例尸解的肺组织标本和患者鼻咽拭子标本中采用细胞培养法分离出病原体。通过电镜在病变细胞及其培养上清中观察到大量冠状病毒样颗粒。免疫荧光染色检测非典型肺炎患者血清,表明分离的病毒与此次流行的非典型肺炎密切相关。分离的病毒可对乳鼠致病,并在发病乳鼠的肺组织标本中通过电镜同样观察到冠状病毒样颗粒。从非典型肺炎病例尸解肺组织、传代发病小鼠肺组织及分离物感染的细胞培养物中,通过RTPCR可分别扩增出冠状病毒的cDNA片段,测序结果显示其核苷酸序列与已知冠状病毒的同源性在60%左右。结论从非典型肺炎病例标本中已成功分离出一种新的冠状病毒,它与此次流行的非典型肺炎密切相关,很可能是此次流行的非典型肺炎的主要病原体 。     

Isolation and Characterization of a Novel Endoglucanase from a Bursaphelenchus xylophilus Metagenomic Library

A novel gene (designated as cen219) encoding endoglucanase was isolated from a Bursaphelenchus xylophilus metagenomic library by functional screening. Sequence analysis revealed that cen219 encoded a protein of 367 amino acids. SDS-PAGE analysis of purified endoglucanase suggested that Cen219 was a monomeric enzyme with a molecular mass of 40 kDa. The optimum temperature and pH for endoglucanase activity of Cen219 was separately 50°C and 6.0. It was stable from 30 to 50°C, and from pH 4.0 to 7.0. The activity was significantly enhanced by Mn²⁺ and dramatically reduced by detergent SDS and metals Fe³⁺, Cu²⁺ or Hg²⁺. The enzyme hydrolyzed a wide range of β-1, 3-, and β-1, 4-linked polysaccharides, with varying activities. Activities towards microcrystalline cellulose and filter paper were relatively high, while the highest activity was towards oat gum. The K_m and V_max of Cen219 towards CMC was 17.37 mg/ml and 333.33 U/mg, respectively. The findings have an insight into understanding the molecular basis of host–parasite interactions in B. xylophilus species. The properties also make Cen219 an interesting enzyme for biotechnological application.     

Isolation and Characterization of a Novel Lysine Racemase from a Soil Metagenomic Library

A lysine racemase (lyr) gene was isolated from a soil metagenome by functional complementation for the first time by using Escherichia coli BCRC 51734 cells as the host and d-lysine as the selection agent. The lyr gene consisted of a 1,182-bp nucleotide sequence encoding a protein of 393 amino acids with a molecular mass of about 42.7 kDa. The enzyme exhibited higher specific activity toward lysine in the l-lysine-to-d-lysine direction than in the reverse reaction.Amino acids are the building blocks of proteins and play an important role in the regulation of the metabolism of living organisms. Among two enantiomers of naturally occurring amino acids, l-amino acids are predominant in living organisms, while d-amino acids are found in both free and bound states in various organisms like bacteria (36), yeasts (35), plants (47), insects (11), mammals (17), bivalves (39), and fish (28). The d-amino acids are mostly endogenous and produced by racemization from their counterparts by the action of a racemase. Thus, the amino acid racemases are involved in d-amino acid metabolism (29, 46). Since the discovery of alanine racemase in 1951 (42), several racemases toward amino acids, such as those for glutamate, threonine, serine, aspartate, methionine, proline, arginine, and phenylalanine, have been reported in bacteria, archaea, and eukaryotes, including mammals (1, 2, 15, 30, 31, 44). They are classified into two groups: pyridoxal 5′-phosphate (PLP)-dependent and PLP-independent enzymes (9, 36).Lysine racemase (Lyr, EC 5.1.1.5) was first reported in Proteus vulgaris ATCC 4669 (19) and proposed to be involved in the lysine degradation of bacterial cells (5, 19). Catabolism of lysine occurs via two parallel pathways. In one of the pathways, δ-aminovalerate is the key metabolite, whereas in the other l-lysine is racemized to d-lysine, and l-pipecolate and α-aminoadipate (AMA) are the key metabolites (5). d-Lysine catabolism proceeds through a series of cyclized intermediates which are necessary to regenerate an α-amino acid and comprise the following metabolites (AMA pathway): d-lysine→α-keto-ɛ-amino caproate→Δ¹-piperideine-2-carboxylate→pipecolate→Δ¹-piperideine-6-carboxylate→α-amino-δ-formylcaproate→α-AMA→α-ketoadipate (6, 7, 12, 27). The final product is converted to α-ketoglutarate via a series of coenzyme A derivatives and subsequently participates as an intermediate in the Krebs cycle. This pathway suggests that the biological function of d-lysine in the bacteria is that of a carbon or nitrogen source. Racemization of added l-lysine to d-lysine by whole cells of Proteus spp. and Escherichia spp. (19) and by the cell extract of Pseudomonas putida ATCC 15070 (5, 20) has been found. However, the enzyme has not been purified to homogeneity, and thus, its molecular and catalytic characteristics, including its gene structure, have not been elucidated. In this study, we explored a metagenomic library constructed from a garden soil to isolate a novel Lyr enzyme. After expression in Escherichia coli, the purified enzyme was characterized in terms of optimal pH and temperature, thermal stability, and racemization activity.     

BCR-ABL Gene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia

Acquired resistance through genetic mutations is a common phenomenon in several cancer therapies using molecularly targeted drugs, best exemplified by the BCR-ABL inhibitor imatinib in treating chronic myelogenous leukemia (CML). Overcoming acquired resistance is a daunting therapeutic challenge, and little is known about how these mutations evolve. To facilitate understanding the resistance mechanisms, we developed a novel culture model for CML acquired resistance in which the CML cell line KCL-22, following initial response to imatinib, develops resistant T315I BCR-ABL mutation. We demonstrate that the emergence of BCR-ABL mutations do not require pre-existing BCR-ABL mutations derived from the original patient as the subclones of KCL-22 cells can form various BCR-ABL mutations upon imatinib treatment. BCR-ABL mutation rates vary from cell clone to clone and passages, in contrast to the relatively stable mutation rate of the hypoxanthine-guanine phosphoribosyltransferase gene. Strikingly, development of BCR-ABL mutations depends on its gene expression because BCR-ABL knockdown completely blocks KCL-22 cell relapse on imatinib and acquisition of mutations. We further show that the endogenous BCR-ABL locus has significantly higher mutagenesis potential than the transduced randomly integrated BCR-ABL cDNA. Our study suggests important roles of BCR-ABL gene expression and its native chromosomal locus for acquisition of BCR-ABL mutations and provides a new tool for further studying resistance mechanisms.     

一种新的源自赤NFDA1的强血管生成抑制剂福安泰-03的分离和鉴定

从赤NFDA1软骨和去皮的软组织中分离并鉴定了一种新的强血管生成抑制剂福安泰-03(Fuantai-03, FAT-03). 利用组织匀浆、盐析、离子交换层析、疏水层析和反向层析等方法进行分离和纯化. 鸡胚绒毛尿囊膜（CAM）试验检测FAT-03对血管生成的影响. SDS-PAGE分析揭示,FAT-03为单一银染条带,分子量大约为43 000.层析洗脱实验证实,这一分子量蛋白质具有强抗血管生成活性. FAT-03的纯度进一步因其独特的N末端氨基酸序列（PFGNTHNKWKLNYSAEQEFP）而肯定.每日20、40和80μg FAT-03给药组（每胚给药3 d）对血管生成的抑制率分别为 23.6%、33.1%和50.8%. 本研究首次证实,赤NFDA1产生上述强血管生成抑制剂.